Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells

Chemico-Biological Interactions

Volumn 117, Issue 2, 1999, Pages 99-115

  Perez, J M ^a   Camazon M ^a   Alvarez Valdes, A ^a   Quiroga, A G ^a   Kelland, L R ^b   Alonso, C ^a   Navarro Ranninger, M C ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cytotoxicity; p53 dependent apoptosis; Pt(IV)

Indexed keywords

PLATINUM COMPLEX; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA CROSS LINKING; DNA MODIFICATION; DRUG SYNTHESIS; GLIOMA CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CROSS-LINKING REAGENTS; DNA, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLIOMA; GLUTARATES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033009162     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00100-8     Document Type: Article

References (42)

1. Rosenberg B. Fundamental studies with cisplatin. Cancer. 55:1985;2303-2316.
2. N. Farrell, Transition Metal Complexes as Drugs and Chemoterapeutic Agents, In: R. Ugo, B.R. James, (eds.), Kluwer Academic Pub. Dordrecht. The Netherlands. 1989.
3. Kelland L.R. New Platinum antitumor complexes. Critical Reviews in Oncology/Hematology. 1993;Elsevier Scientific.
4. R.B. Weiss, M.C. Christian, New cisplatin analoguoes in development. A review, Addis International Limited, 1993.
5. J. Reedijk, Improved understanding in platinum antitumor chemistry, Chem. Commun. (1996) 801.
6. Calvert A.H., Harland S.J., Newell D.R., Siddik Z.H., Harrap K.R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat. Rev. 12:1985;21-33.
7. Kelland L.R., Murrer B.A., Abel G., Harrap K.R Stucture activity relationships in a series of novel Platinum (II) and platinum (IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell. J. Cell Pharmacol. 2:1991;331.
8. Kelland L.R., Murrer B.A., Abel G., Giandomenico C.M., Mismy P., Harrap K.R. Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 52:1992;822-828.
9. Kido Y., Khokhar A.R., Siddijk Z.H. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anti Cancer Drugs. 4:1993;251-258.
10. Bramwell V.H.C., Crowther D., Malley S.O., Swindell R., Johnson R., Creaven E. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Cancer Treat. Rep. 69:1985;409-416.
11. Harrap K.R., Murrer B.A., Giandomenico C., Morgan S.E., Kelland L.R., Jones M., Goddard P. M., Schurig J. Howell S. B. Platinum and other Metal Complexes in Cancer Chemotherapy. 1991;Plenum Press, New York.
12. Giandomenico C.M., Abrams M.J., Murrer B.A., Vrelano J.F., Rheinheimer M.I., Wyer S.B., Bossard G.E., Higgins J.D. Carboxylation of kinetically Inert platinum (IV) hydroxy complexes. An entree into orally active platinum (IV) antitumor agents. Inorg. Chem. 34:1995;1015-1021.
13. Kelland L., Neidle S., Snook C.F., Murrer B.A., Barnard C.F.J. Bis(acetato)amminedichloro(cyclohexylamine) platinum (IV) and orally active anticancer drug. Acta Crystallogr. C51:1995;882.
14. Kelland L.R., Abel G., McKeage M.J., Jones M., Goddard P.M., Valenti M., Murrer B.A., Harrap K.R. Preclinical antitumor evaluation of bisacetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res. 53:1993;2581-2586.
15. I. Judson, M. Mckeage, F. Raynaud, J. Hanwell, C. Berry, B. Murrer, D. Crabells, K. Harrap, (1995). Book of Abstracts: 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemoterapy. European Cancer Centre: Amsterdam. (1995). pp 054.
16. F. Raynaud, F. Boxall, M. Goddard, M. Valenti, C. Barnard, B. Murrer, L. Kelland, K. Harrap, Book of Abstracts: 7th international Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemoterapy, European Cancer Centre: Amsterdam, (1995) pp 074.
17. Ellis R.E., Yuan J., Horvitz H.R. Mechanisms and functions of cell death. Annul Rev. Cell Biol. 7:1991;398-663.
18. Steller H. Mechanisms and genes of cellular suicide. Science. 267:1995;1445-1449.
19. Hickman J.A. Apoptosis induced by anticancer agents. Cancer Metastasis Rev. 11:1992;121-139.
20. Dive C., Wyllie A.H. Apoptosis and cancer chemotherapy. Hickman J.A., Tritton T.R. Frontiers in Pharmacology. 1993;21-56 Blackwell Scientific, Oxford.
21. Williams G.T. Programmed cell death: apoptosis and oncogenesis. Cell. 65:1991;1-2.
22. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis, a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer. 26:1972;239-257.
23. Arends M.J., Wyllie A.H. Apoptosis: mechanisms and role in pathology. Int. Rev. Exp. Pathol. 32:1991;223-254.
24. Wyllie A.X, Kerr J.F.R., Currie A.R. Cell death: the significance of apoptosis. Bourne G.H., Danielli F.J., Jeon K.W. International Review of Cytology. 68:1980;251-306 Academic Press, New York.
25. Ko L.J., Prives C. P53: puzzle and paradigm. Genes Dev. 10:1996;1051-1072.
26. Levine A.J. P53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
27. Perego P., Giarola M., Righetti S.C., Supino R., Caserini C., Delia D., Pierotti M.A., Miyashita T., Reed J.C., Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56:1996;556-562.
28. Gallagher W.M., Cairney M., Schott B., Roninson I.B., Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene. 14:1997;185-193.
29. De Feudis P., Debernardis D., Beccaglia P., Valenti M., Graniela Síre E., Arzani D., Stanzione S., Parodi S., D'Incalci M., Russo P. et al. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cells. Br. J. Cancer. 76:1997;474-479.
30. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace Jr A.J., Kohn K. Characterization of the p53 tumor suppressor pathway in cell dines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
31. Burger H., Nooter K., Boersma A.W., Ko M., Kortland C.J., Stoter G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bc1-2 family proteins in testicular germ cell tumour cell lines. Int. J. Cancer. 73:1997;592-599.
32. Zamble D.B., Jacks T., Lippard S.J. P53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. USA. 95:1998;6163-6168.
33. Kohn K.W., Ewig R.A.G., Erickson L.C., Zwelling L.A. Friedberg E.C., Hanawalt P.C. DNA repair. A laboratory manual of research procedures, pt. B. 1981;379-401 Marcel Dekker, New York.
34. Fichtinger-Schepman A.M.J., van der Veer J.L., den Hartog J.H.J., Lohman P.H.M., Reedjik J. Adducts of the antitumour drug cis diaminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry. 24:1985;707-713.
35. Pinto A.L., Lippard S.J. Binding of the antitumor drug cis diaminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta. 780:1985;167-180.
36. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 2:1990;275-280.
37. Dhara S.C. A rapid method for the synthesis of cis-[Pt(NH3)Cl2]. Indian J. Chem. 8:1970;193-194.
38. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
39. Skehan P., Storeng R., Scudiero D., Monks A., Mcmahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1113-1118.
40. Benito A., Silva M., Grillot D., Nunez G., Fernandez-Luna J.L Apoptosis induced by erythroid differentation of human leukemia cell lines is inhibited by BclXL. Blood. 87:1996;3837-3843.
41. Zaludova R., Zakovska A., Kasparkova J., Balcarova Z., Vrana O., Coluccia M., Natile G., Bravec V. DNA modifications by antitumor trans-[PtCl2 (E-iminoether)2]. Mol. Pharmacol. 52:1998;354-361.
42. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.